Quarterly report · Q1
3353.TEDINET S100OPR7
Period2022-03-01 → 2022-05-31
Filed2022-07-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.6bn | 2022-03-01 → 2022-05-31 | Cons. | Net sales |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.5bn | 2021-03-01 → 2021-05-31 | Cons. | Net sales |
| Operating income | ¥239m | 2022-03-01 → 2022-05-31 | Cons. | Operating income |
| Operating income | ¥303m | 2021-03-01 → 2021-05-31 | Cons. | Operating income |
| Ordinary income | ¥313m | 2022-03-01 → 2022-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥316m | 2021-03-01 → 2021-05-31 | Cons. | Ordinary income |
| Profit before tax | ¥334m | 2022-03-01 → 2022-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥386m | 2021-03-01 → 2021-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥208m | 2022-03-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥226m | 2021-03-01 → 2021-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥213m | 2022-03-01 → 2022-05-31 | Cons. | Profit loss |
| Net income | ¥226m | 2021-03-01 → 2021-05-31 | Cons. | Profit loss |
| Total assets | ¥28.8bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥29.1bn | at 2022-02-28 | Cons. | Assets |
| Total assets | ¥28.3bn | at 2021-05-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.8bn | at 2022-05-31 | Cons. | Liabilities |
| Total liabilities | ¥17.2bn | at 2022-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥12.0bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28 | Cons. | Net assets |
| Net assets / equity | ¥10.6bn | at 2021-05-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.3bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥8.0bn | at 2022-02-28 | Cons. | Cash and deposits |
| EPS (basic) | ¥55.39 | 2022-03-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.09 | 2021-03-01 → 2021-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 39.8% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.5% | at 2021-05-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-05-31 | −¥253m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-05-31 | −¥253m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-05-31 | −¥189m |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥5.9bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥363m |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥1.9bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥1.9bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥150,000 |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥19m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥946m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥694m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥252m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥16m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-05-31 | ¥49m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-05-31 | ¥49m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥381,000 |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-05-31 | ¥30m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-05-31 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-05-31 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-05-31 | ¥253m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-05-31 | ¥428m |
| Reconciling Itemsreconciling | revenue | 2021-03-01 → 2021-05-31 | −¥278m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-03-01 → 2021-05-31 | −¥278m |
| Reconciling Itemsreconciling | segment profit | 2021-03-01 → 2021-05-31 | −¥180m |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2021-03-01 → 2021-05-31 | ¥5.8bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2021-03-01 → 2021-05-31 | ¥5.8bn |
| jpcrp040300-q1r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2021-03-01 → 2021-05-31 | ¥340m |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue | 2021-03-01 → 2021-05-31 | ¥2.0bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue external | 2021-03-01 → 2021-05-31 | ¥2.0bn |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | revenue intersegment | 2021-03-01 → 2021-05-31 | ¥150,000 |
| jpcrp040300-q1r_E03443-000Health Carereportable segment | segment profit | 2021-03-01 → 2021-05-31 | ¥74m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue | 2021-03-01 → 2021-05-31 | ¥1.0bn |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2021-03-01 → 2021-05-31 | ¥726m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2021-03-01 → 2021-05-31 | ¥278m |
| jpcrp040300-q1r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2021-03-01 → 2021-05-31 | ¥36m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue | 2021-03-01 → 2021-05-31 | ¥59m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue external | 2021-03-01 → 2021-05-31 | ¥58m |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | revenue intersegment | 2021-03-01 → 2021-05-31 | ¥540,000 |
| jpcrp040300-q1r_E03443-000Real Estatereportable segment | segment profit | 2021-03-01 → 2021-05-31 | ¥33m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-03-01 → 2021-05-31 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-03-01 → 2021-05-31 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-03-01 → 2021-05-31 | ¥278m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-03-01 → 2021-05-31 | ¥483m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 353
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |